Related Experiment Video
Updated: Aug 17, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Abstract:
The isomeric mixtures of platinum complexes of diaminocyclohexane (DACH) had been found active on several murine tumors. A recent separation of the oxalato-platinum complex of trans-l-DACH isomer allowed more precise screening studies and permitted the selection of one compound: l-OHP was submitted to our murine tumor screening system. The drug was given: (a) at doses of 1-12 mg/kg i.p. or i.v. on day 1, 5 and 9 compared to identical doses of cis-dichlorodiamine platinum II (CDDP) in L1210 bearing mice and (b) to AkR leukemia, LGC lymphoma, glioma 26, B16 melanoma, MA 16-C mammary carcinoma and Lewis lung carcinoma bearing mice at 2 dosages: 5 mg/kg (minimal effective dose on L1210), and 8 mg/kg (subtoxic dose in L1210). Acute LD10 and LD50 appeared similar to CDDP and l-OHP. l-OHP administered i.p. was more active on L1210 than CDDP. On L1210 grafted intracerebrally and on LGC lymphoma l-OHP increased significantly the lifespan while CDDP was inactive. On AkR leukemia, both drugs were active but l-OHP was less toxic. Both drugs were inactive on murine solid tumors. No renal toxicity was observed with l-OHP as compared to CDDP.
Insights
The platinum complex l-OHP shows promise as an anti-cancer drug, demonstrating superior activity against certain murine leukemias and lymphomas compared to CDDP, with reduced toxicity and no observed renal damage.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Diaminocyclohexane (DACH) platinum complexes exhibit anti-tumor activity.
- Separation of the oxalato-platinum complex of trans-l-DACH isomer led to the selection of l-OHP for further study.
Purpose of the Study:
- To evaluate the efficacy and toxicity of l-OHP in a murine tumor screening system.
- To compare l-OHP's activity and toxicity with cis-dichlorodiamine platinum II (CDDP).
Main Methods:
- l-OHP was administered intraperitoneally (i.p.) or intravenously (i.v.) to mice bearing L1210 leukemia, compared with CDDP.
- l-OHP was tested at minimal effective and subtoxic doses on AkR leukemia, LGC lymphoma, glioma 26, B16 melanoma, MA 16-C mammary carcinoma, and Lewis lung carcinoma.
- Acute toxicity (LD10 and LD50) was assessed for both drugs.
Main Results:
- l-OHP demonstrated greater activity than CDDP against L1210 leukemia when administered i.p.
- l-OHP significantly increased lifespan in mice with intracerebral L1210 leukemia and LGC lymphoma, where CDDP was ineffective.
- Both drugs were active against AkR leukemia, but l-OHP exhibited lower toxicity.
- Neither drug showed activity against tested murine solid tumors.
- l-OHP did not cause renal toxicity, unlike CDDP.
Conclusions:
- l-OHP is a promising anti-cancer agent with improved efficacy and reduced toxicity compared to CDDP, particularly against certain leukemias and lymphomas.
- l-OHP warrants further investigation as a potential therapeutic agent, especially for central nervous system malignancies due to its activity against intracerebral L1210.
- The lack of renal toxicity makes l-OHP a potentially safer alternative to CDDP.
